Reactions 427 - 14 Nov 1992

SAntineoplastics

Myelodysplastic syndrome in children: 2 casereports

Pancytopenia developed 19 months after the completion of2 years’ antineoplastic therapy comprising chlormethine,vincristine, procarbazine and prednisone (MOPP), in a 4-year-old girl with medulloblastoma. In this child, myelodysplasticsyndrome (MDS) was diagnosed based on a complete bloodcount and bone marrow examination. Acute myelomonocyticleukaemia developed 7 months later, and the child eventuallydied after a brief response to further antineoplastic therapy. Asecond girl, aged 8 years, was diagnosed with MDS 5 monthsafter the completion of MOPP therapy for medulloblastoma.No treatment was given and she remained moderatelypancytopenic 13 months after the completion of MOPPtherapy Author comment: ‘The association between MOPPtherapy and second malignancies in patients with Hodgkin’sDisease is well recognized. A similar association is not wellrecognized in children receiving MOPP chemotherapy forbrain tumors ... Although we cannot conclude that MOPPtherapy caused MDS in our two patients, it is most likely thatMOPP played a major role in the pathogenesis of MDS.’Hayani A, et al. Therapy-related myelodysplastic syndrome in children withmedulloblastoma following MOPP chemotherapy. Journal of Neuro-Oncology 14:57-62, Sep 1992 - 807002343

1

Reactions 14 Nov 1992 No. 4270114-9954/10/0427-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved